Underweight CL with staged trim to 50%-70% and $90 covered-call overlay to convert alpha-bleed setup into defensive carry
Underweight CL with staged trim toward 50%-70% of normal/benchmark position and covered-call overlay on residual core at $90 strike. Bear evidence (operating income decline, expanding MACD, stacked overhead resistance, fair-not-cheap valuation at 22× forward P/E, PEG ~1.77, US consumer softness) outweighs bull framing at $89.58 near lower Bollinger test. Franchise thesis intact (Hill's recovery, buyback flywheel, 63-year dividend streak, 2.5× FCF coverage, macro defensive bid), warranting residual defensive core rather than full exit. The $90 strike calibration reflects the 8/20 lesson on strike proximity; the staged trim reflects 8/19 and 8/12 lessons on bare Hold alpha ceilings and trim-without-carry giving up upside without harvesting carry. Price target $90.
| Position | Action |
|---|---|
| Current position at normal/mid-range sizing | Trim toward 50%-70% of normal/benchmark position |
| Stabilized pullback into $87.50-$86.16 zone with improving momentum | Consider re-engaging to residual defensive core sized for 4%-5% drawdown to 200 SMA |
| Hard stop triggered: close below $86.16 with volume >4M | Exit remaining position on closing basis |
CL at $89.70 is a high-conviction BUY on this dip, offering a highly asymmetric risk/reward with limited downside to the high-$80s (200 SMA at $86.16) and material upside to $95-98 over 6-9 months, supported by accelerating fundamentals, margin expansion, raised guidance, and a fortress balance sheet in a benign macro environment.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | $86.16 | bullish |
| close_50_sma | $91.48 | bearish |
| close_10_ema | $91.36 | bearish |
| rsi | 42.65 | bearish |
| macd | -0.15 | bearish |
| macdh | -0.33 | bearish |
| boll_middle | $91.94 | bearish |
| atr | 2.12 | neutral |
Support: 89.58 · 86.16 · 87.5 | Resistance: 91.36 · 91.48 · 91.94 · 94.29 · 95.46
CL shows a dual-speed trend structure with long-term bullish conviction (price firmly above 200 SMA) but short-term bearish deterioration across all momentum and moving average indicators. The critical inflection point is the Bollinger lower band at $89.58 — a breakdown would target $86.16 (200 SMA), while a reclaim of $91.48 (50 SMA) would neutralize bearish bias and signal the pullback's end. ATR compression to 2.12 from a peak of 2.55 suggests a coiled-spring volatility expansion is imminent, likely to resolve the Bollinger band test. Defensive consumer staples dynamics historically treat drawdowns of this magnitude (~6% from $95.46) as buying opportunities if the 200 SMA holds, supporting the HOLD recommendation with clear upgrade/downgrade triggers.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Stabilized pullback into $87.50-$86.16
Then: Re-engage/accumulate at support
The technical pullback to $89.70 is a healthy correction within a structural uptrend, with strong support at the 200 SMA of $86.16.
EV: +17% to +22% · concedes: MACD crossed negative — a real signal that suggests waiting for confirmation; RSI at 42.65 indicates near-term weakness; Stock is below the 50-day SMA at $91.48; KMB's China diaper warning is real and EM concerns are valid; Walmart US sales call was a weak data point for the sector
CL is a quality company at a bad price in a deteriorating technical setup with consensus-priced tailwinds — a potential value trap where 18.36% YTD outperformance has already priced in the bull case.
EV: -$3.50+ downside to $86.16 (200 SMA) vs $1.70 upside to $91.48 (50 SMA); asymmetric risk/reward to downside · concedes: Quality of balance sheet is real: net debt down $1B, current ratio 1.03, $3.46B FCF; Q2 revenue beat and guidance raise are real achievements; The bull is right that the company has quality characteristics — the bear case is about price, not quality
→ vs conservative: SELL call on a 6% pullback in a fundamentally improving dividend king is a dereliction of duty; trimming 3 points above the 200-day MA because MACD had six red prints is selling into weakness
→ vs conservative: TTM PE of 35.9 is misleading due to one-time charge; forward multiple of 22x matches P&G and KMB on superior margin and FCF profile
→ vs neutral: MACD histogram expansion from -0.05 to -0.33 is textbook late-stage fear, not a warning — it's a reason to load the boat on quality at a discount
→ vs neutral: Walmart's weak US sales read supports CL's defensive outperformance thesis as money rotates from discretionary into defensive HPC names
→ vs neutral: 'Staged reduction to 50-70%' framing is the most timid interpretation; asymmetry is backward — don't trim near major support, add on confirmation
Market Cap
$72.6B
Current Price (50-DMA proxy)
~$91.75
52-Week Range
$74.55 – $99.33
Beta
0.327
Dividend Yield
2.36%
PE (TTM)
35.86
Forward PE
22.17
PEG Ratio
1.75
Price / Book
307.7
Q2 2026 Revenue
$5,361M
Q2 2026 Gross Profit
$3,296M
Q2 2026 Operating Income
$1,016M
Q2 2026 Net Income
$693M
Q2 2026 Diluted EPS
$0.86
Q1 2026 Revenue
$5,324M
Q1 2026 Net Income
$646M
Q1 2026 Diluted EPS
$0.80
Q4 2025 Revenue
$5,230M
Q4 2025 Operating Income
$92M
Q4 2025 Net Income
($37M)
Q4 2025 Diluted EPS
($0.05)
Q4 2025 Normalized EBITDA
$1.217B
Q3 2025 Revenue
$5,131M
Q3 2025 Net Income
$735M
Q3 2025 Diluted EPS
$0.91
Q2 2025 Revenue
$5,110M
Q2 2025 Net Income
$743M
Q2 2025 Diluted EPS
$0.91
Gross Margin (TTM)
~60.4%
Operating Margin
20.97%
EBITDA Margin
~23.7%
Net Profit Margin
9.68%
Return on Equity (ROE)
267.4%
Return on Assets (ROA)
15.84%
Total Assets
$16,790M
Total Liabilities
$16,224M
Stockholders' Equity
$236M
Treasury Stock
$28,931M
Goodwill + Intangibles
$4,595M
Net PPE
$4,639M
Cash & Equivalents
$1,370M
Inventory
$2,181M
Receivables
$1,962M
Total Debt
$7,857M
Net Debt
$6,487M
Long-Term Debt
$7,823M
Current Portion of Debt
$34M
Current Ratio
1.03
Working Capital
$160M
Operating Cash Flow
$995M
Capital Expenditures
($128M)
Free Cash Flow (Quarter)
$867M
FCF (TTM)
$3,458M
Dividends Paid (Quarter)
($462M)
Buybacks (Quarter)
($291M)
Q4 2025 FCF
$1,276M
Q3 2025 FCF
$1,106M
Q2 2025 FCF
$776M
Q1 2026 FCF
$609M
Annualized Dividend Run Rate
~$1.85B
Annualized Buybacks
~$1.2B
Total Capital Return (Annualized)
~$3.05B
Share Count
800M
Forward EPS
$4.11
TTM EPS (Normalized)
$2.54
Underlying Quarterly EPS
~$0.85-0.91
YoY Revenue Growth (Q2)
+4.9%
Expected Normalized Growth
5-8%
Emerging Markets Revenue Exposure
~40%
Strengths
Concerns
Colgate-Palmolive (CL) is a mega-cap consumer defensive franchise trading at $91.75 with a forward PE of 22.17x, offering a 2.36% dividend yield backed by 60+ years of consecutive dividend growth. The company demonstrates exceptional profitability (60.4% gross margin, 15.8% ROA) and FCF generation ($3.46B TTM), though organic growth is slow at ~5% and 40% revenue exposure to emerging markets creates FX headwinds. The Q4 2025 $866M one-time charge distorted TTM metrics; excluding this, underlying EPS runs ~$0.85-0.91/quarter with normalized growth expected at 5-8%. Capital return is aggressive with ~$3.05B annualized returned to shareholders via dividends and buybacks, funded by the company's asset-light model and declining debt ($7.86B from $8.76B YoY).
Macro: Disinflationary, hawkish-on-cuts, low-recession-risk environment. Polymarket prices 85% odds of zero Fed cuts in 2026 and only 8% odds of a US recession by year-end. Rate path is supportive of duration-sensitive defensive equities; zero-cut, low-recession regime historically favors staples multiples. US consumer is softening (Walmart "worst-case" US sales read, $89B WMT drawdown, Amazon/Home Depot also weaker) — yellow flag for CL's US volumes. Japan recession odds rose 10.5 pp to 36% — watch for cross-border HPC supply chain and demand propagation. Energy-driven input cost relief (oil topping/halting, US-Iran de-escalation signal) is a marginal tailwind for packaging and surfactants in HPC. China demand (via Japan recession proxy, KMB China diaper disruption precedent) is the cross-border risk worth monitoring.